Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact

Andrew Bate^{1

2}

Affiliations

Comment

Andrew Bate. Pharmacoepidemiol Drug Saf. 2017 Sep.

. 2017 Sep;26(9):1013-1017.

doi: 10.1002/pds.4305.

Andrew Bate^{1

2}

No abstract available

Keywords: RWE guidance; database study reporting; health care database study; pharmacoepidemiology; replicability; reproducibility.

Comment on

Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.
Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. Wang SV, et al. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1018-1032. doi: 10.1002/pds.4295. Pharmacoepidemiol Drug Saf. 2017. PMID: 28913963 Free PMC article.
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel Mullins C. Berger ML, et al. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-1039. doi: 10.1002/pds.4297. Pharmacoepidemiol Drug Saf. 2017. PMID: 28913966 Free PMC article.